Total Funding
89
43
Total FundingGrant raised
Growth Score
-5 pts
Heat Score
5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
20986
Allegria Therapeutics is a biotech firm that engages in the research and treatment of allergy and mast cell-mediated inflammatory diseases.
- Maria Van Dongen: CEO & Co-founderPast Role: Johnson & Johnson Impact Ventures, Head of External Innovation, Therapeutics Discovery / DPDS
About the Company
Allegria Therapeutics focuses on developing targeted therapies for cancer and other serious diseases using innovative drug delivery platforms. The company specializes in creating novel treatments that enhance the precision and effectiveness of therapeutic agents while minimizing side effects. Its approach involves utilizing proprietary technologies
to improve the delivery of drugs to specific cells or tissues, optimizing their therapeutic impact. Allegria Therapeutics collaborates with scientific and medical experts to advance its pipeline of products and address unmet medical needs. The company is dedicated to transforming patient care by providing solutions that aim to improve outcomes in complex and challenging health conditions.
